GLP-2 Tirzepatide (40mg vials)
Price range: $260.00 through $3,090.00
For Research Use Only. Not for Use in diagnostic procedures.
This product is solely intended for research purposes as a chemical compound. Its designation permits its use exclusively for in vitro testing and laboratory experimentation. All information regarding this product provided on our website is purely educational. By law, any form of bodily introduction of this product into humans or animals is strictly prohibited. It should only be handled by professionals who are licensed and qualified. This product is neither a drug, food, nor cosmetic, and must not be misrepresented, misused, or mislabeled as such.
🔥 Exclusive Crypto Offer
Get an INSTANT 15% DISCOUNT when you pay with Bitcoin, Ethereum, Dogecoin, Bitcoin Cash, XRP, Solana, or USDT.
⚡ Don't have crypto? Buy it here in 5 minutes with easy guidance.
đź’ˇ Pro Tip: You can also pay with cryptocurrency using your verified Cash App or PayPal account for a fast and secure checkout!
GLP-2 Tirzepatide
Swipe right to view full table →
Save over 80%!
Product Format |
40mg vials |
Vial Size |
40mg |
Vial Capacity |
3 mL |
Box Combinations |
80mg, 200mg, 400mg, 800mg, 1200mg |
Cost per milligram |
$2.58 – $3.25 |
Multi-vial Purity |
99.44% |
Endotoxin Screening |
PASSED |
Heavy Metals Screening |
PASSED |
Purity Screening |
PASSED |
Doubly Validated |
YES |
Independently Tested |
YES |
- Peptide Partners Manufacturer ID: WF03
- Batch ID: TZ202605
Research Studies
(for educational purposes only)
Study 1: Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Authors: Willard FS, Douros JD, Showalter AD, Wainscott DB, Suter TM, Capozzi ME, Cardona GR, Urva S, Emmerson PJ, Rosenkilde MM, Campbell JE, Sloop KW
Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC7526454/
Scientific Findings
Studies of the dual GIP and GLP-1 receptor agonist tirzepatide reveal occupancy favoring the GIP receptor and biased cAMP signaling at the GLP-1 receptor. Pharmacological characterization shows tirzepatide is an imbalanced agonist with full efficacy at GIPR but only partial efficacy at GLP-1R, exhibiting biased signaling that favors cAMP over β-arrestin recruitment. It differentially induces internalization of GIPR versus GLP-1R, with full internalization of GIPR but limited internalization of GLP-1R. Ex vivo experiments using pancreatic islets indicate that β-arrestin1 limits insulin response to GLP-1 but not GIP or tirzepatide, supporting a distinct signaling profile. The study also introduces receptor occupancy estimation methods, highlighting the pharmacological basis for tirzepatide’s efficacy and suggesting that biased agonism and receptor engagement contribute to its metabolic benefits.
Plain English Interpretation
This research explains how tirzepatide works at the molecular level. It mainly activates the GIP receptor strongly but only partly activates the GLP-1 receptor, and it prefers certain signaling pathways over others. This unique activity may help explain why tirzepatide is effective in lowering blood sugar and reducing weight. It also shows that tirzepatide affects the receptors differently, internalizing GIP receptors fully but only partially affecting GLP-1 receptors. These findings help us understand how tirzepatide improves metabolic health and can guide the development of future treatments.
Study 2: Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor
Authors: Ajit Regmi, Eitaro Aihara, Michael E. Christe, Gabor Varga, Thomas P. Beyer, Xiaoping Ruan, Emily Beebe, Libbey S. O’Farrell, Melissa A. Bellinger, Aaron K. Austin, Yanzhu Lin, Haitao Hu, Debra L. Konkol, Samantha Wojnicki, Adrienne K. Holland, Jessica L. Friedrich, Robert A. Brown, Amanda S. Estelle, Hannah S. Badger, Gabriel S. Gaidosh, William Roell
Source: https://www.sciencedirect.com/science/article/pii/S1550413124001864
Scientific Findings
Using human adipocyte and mouse models, we investigated how long-acting GIPR agonists regulate fasted and fed adipocyte functions. In functional assays, GIPR agonism enhanced insulin signaling, augmented glucose uptake, and increased the conversion of glucose to glycerol in a cooperative manner with insulin; however, in the absence of insulin, GIPR agonists increased lipolysis. In diet-induced obese mice treated with a long-acting GIPR agonist, circulating triglyceride levels were reduced during oral lipid challenge, and lipoprotein-derived fatty acid uptake into adipose tissue was increased. Our findings support a model for long-acting GIPR agonists to modulate both fasted and fed adipose tissue function differentially by cooperating with insulin to augment glucose and lipid clearance in the fed state while enhancing lipid release when insulin levels are reduced in the fasted state.
Plain English Interpretation
This study shows that tirzepatide, a drug that activates GIP and GLP-1 receptors, can directly affect fat cells by increasing their ability to take up and store nutrients when insulin is present (fed state) and promoting fat breakdown when insulin is low (fasted state). These effects help improve blood sugar and lipid levels without increasing fat mass, offering a better understanding of how tirzepatide works to improve metabolic health in diabetes and obesity.
Study 3: GLP-1/GIP dual agonist tirzepatide normalizes diabetic nephropathy via PI3K/AKT mediated suppression of oxidative stress
Authors: Yan Tian, Ruixue Tian, He Juan, Yafan Guo, Pan Yan, Yao Cheng, Rongshan Li, Baodong Wang
Source: https://www.sciencedirect.com/science/article/pii/S1567576924023993
Scientific Findings
The study investigates the effects of the dual GLP-1/GIP receptor agonist tirzepatide on diabetic nephropathy (DN) in mice and in vitro podocyte cells. It demonstrates that tirzepatide reduces glucose levels, body weight, and urine albumin-to-creatinine ratio, and enhances antioxidative stress activities, similar to semaglutide, at a dose one-third lower. Transcriptome sequencing revealed that tirzepatide significantly enriches the PI3K-AKT signaling pathway, which was validated by Western blot and immunohistochemistry showing activation of this pathway. In vitro, tirzepatide regulated oxidative stress and the PI3K-AKT pathway in high glucose-exposed podocytes, with its antioxidative effects reversed by a PI3K inhibitor. These findings suggest tirzepatide mitigates DN by activating the PI3K/AKT pathway, reducing oxidative stress and podocyte injury, independent of its hypoglycemic effects.
Plain English Interpretation
This study shows that tirzepatide can protect kidneys from damage caused by diabetes. It works by activating a specific signaling pathway (PI3K/AKT) that helps reduce harmful oxidative stress in kidney cells. This protective effect was observed in both diabetic mice and in lab-grown kidney cells, and it works independently of tirzepatide’s ability to lower blood sugar. This suggests that tirzepatide has direct protective effects on the kidneys, which could be beneficial for patients with diabetic kidney disease.
GLP-2 Tirzepatide
Swipe right to view full table →
Save over 80%!
Product Format |
40mg vials |
Vial Size |
40mg |
Vial Capacity |
3 mL |
Box Combinations |
80mg, 200mg, 400mg, 800mg, 1200mg |
Cost per milligram |
$2.58 – $3.25 |
Multi-vial Purity |
99.44% |
Endotoxin Screening |
PASSED |
Heavy Metals Screening |
PASSED |
Purity Screening |
PASSED |
Doubly Validated |
YES |
Independently Tested |
YES |
- Peptide Partners Manufacturer ID: WF03
- Batch ID: TZ202605
Research Studies
(for educational purposes only)
Study 1: Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Authors: Willard FS, Douros JD, Showalter AD, Wainscott DB, Suter TM, Capozzi ME, Cardona GR, Urva S, Emmerson PJ, Rosenkilde MM, Campbell JE, Sloop KW
Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC7526454/
Scientific Findings
Studies of the dual GIP and GLP-1 receptor agonist tirzepatide reveal occupancy favoring the GIP receptor and biased cAMP signaling at the GLP-1 receptor. Pharmacological characterization shows tirzepatide is an imbalanced agonist with full efficacy at GIPR but only partial efficacy at GLP-1R, exhibiting biased signaling that favors cAMP over β-arrestin recruitment. It differentially induces internalization of GIPR versus GLP-1R, with full internalization of GIPR but limited internalization of GLP-1R. Ex vivo experiments using pancreatic islets indicate that β-arrestin1 limits insulin response to GLP-1 but not GIP or tirzepatide, supporting a distinct signaling profile. The study also introduces receptor occupancy estimation methods, highlighting the pharmacological basis for tirzepatide’s efficacy and suggesting that biased agonism and receptor engagement contribute to its metabolic benefits.
Plain English Interpretation
This research explains how tirzepatide works at the molecular level. It mainly activates the GIP receptor strongly but only partly activates the GLP-1 receptor, and it prefers certain signaling pathways over others. This unique activity may help explain why tirzepatide is effective in lowering blood sugar and reducing weight. It also shows that tirzepatide affects the receptors differently, internalizing GIP receptors fully but only partially affecting GLP-1 receptors. These findings help us understand how tirzepatide improves metabolic health and can guide the development of future treatments.
Study 2: Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor
Authors: Ajit Regmi, Eitaro Aihara, Michael E. Christe, Gabor Varga, Thomas P. Beyer, Xiaoping Ruan, Emily Beebe, Libbey S. O’Farrell, Melissa A. Bellinger, Aaron K. Austin, Yanzhu Lin, Haitao Hu, Debra L. Konkol, Samantha Wojnicki, Adrienne K. Holland, Jessica L. Friedrich, Robert A. Brown, Amanda S. Estelle, Hannah S. Badger, Gabriel S. Gaidosh, William Roell
Source: https://www.sciencedirect.com/science/article/pii/S1550413124001864
Scientific Findings
Using human adipocyte and mouse models, we investigated how long-acting GIPR agonists regulate fasted and fed adipocyte functions. In functional assays, GIPR agonism enhanced insulin signaling, augmented glucose uptake, and increased the conversion of glucose to glycerol in a cooperative manner with insulin; however, in the absence of insulin, GIPR agonists increased lipolysis. In diet-induced obese mice treated with a long-acting GIPR agonist, circulating triglyceride levels were reduced during oral lipid challenge, and lipoprotein-derived fatty acid uptake into adipose tissue was increased. Our findings support a model for long-acting GIPR agonists to modulate both fasted and fed adipose tissue function differentially by cooperating with insulin to augment glucose and lipid clearance in the fed state while enhancing lipid release when insulin levels are reduced in the fasted state.
Plain English Interpretation
This study shows that tirzepatide, a drug that activates GIP and GLP-1 receptors, can directly affect fat cells by increasing their ability to take up and store nutrients when insulin is present (fed state) and promoting fat breakdown when insulin is low (fasted state). These effects help improve blood sugar and lipid levels without increasing fat mass, offering a better understanding of how tirzepatide works to improve metabolic health in diabetes and obesity.
Study 3: GLP-1/GIP dual agonist tirzepatide normalizes diabetic nephropathy via PI3K/AKT mediated suppression of oxidative stress
Authors: Yan Tian, Ruixue Tian, He Juan, Yafan Guo, Pan Yan, Yao Cheng, Rongshan Li, Baodong Wang
Source: https://www.sciencedirect.com/science/article/pii/S1567576924023993
Scientific Findings
The study investigates the effects of the dual GLP-1/GIP receptor agonist tirzepatide on diabetic nephropathy (DN) in mice and in vitro podocyte cells. It demonstrates that tirzepatide reduces glucose levels, body weight, and urine albumin-to-creatinine ratio, and enhances antioxidative stress activities, similar to semaglutide, at a dose one-third lower. Transcriptome sequencing revealed that tirzepatide significantly enriches the PI3K-AKT signaling pathway, which was validated by Western blot and immunohistochemistry showing activation of this pathway. In vitro, tirzepatide regulated oxidative stress and the PI3K-AKT pathway in high glucose-exposed podocytes, with its antioxidative effects reversed by a PI3K inhibitor. These findings suggest tirzepatide mitigates DN by activating the PI3K/AKT pathway, reducing oxidative stress and podocyte injury, independent of its hypoglycemic effects.
Plain English Interpretation
This study shows that tirzepatide can protect kidneys from damage caused by diabetes. It works by activating a specific signaling pathway (PI3K/AKT) that helps reduce harmful oxidative stress in kidney cells. This protective effect was observed in both diabetic mice and in lab-grown kidney cells, and it works independently of tirzepatide’s ability to lower blood sugar. This suggests that tirzepatide has direct protective effects on the kidneys, which could be beneficial for patients with diabetic kidney disease.
Third-party testing
Peptide Partners is committed to providing high-purity peptides at wholesale prices by frequently auditing its manufacturing partners using third-party laboratories. Independent analysis is vital to ensuring the quality and authenticity of your research peptides. Never trust a supplier that doesn’t submit to third-party testing. Never trust a certification that cannot be independently verified. All of the certificates that we provide can be validated on the third-party laboratory’s website.
Each product description contains a Manufacturer ID corresponding to the producer of that product. The table below contains the most recent third-party analyses for all manufacturers and peptides listed on Peptide Partners.
Current Purity certifications
Swipe right to view full table →
| Peptide | Batch Id | Manufacturer | Date | Purity | Laboratory | Double Validated | |
|---|---|---|---|---|---|---|---|
| Kisspeptin-10 | KSS2607 | VI32 | 2026-07-02 | 99.71% | Kovera | View File | |
| Reconstitution Solution | BAC202606 | WF03 | 2026-07-13 | 99.9% | Kovera | View File | |
| Retatrutide | RTT2613 | WF03 | 2026-07-02 | 99.77% | Kovera | View File | |
| PT-141 | PT202605 | VI32 | 2026-06-25 | 99.74% | Kovera | View File | |
| Tesamorelin | TES202607 | WF03 | 2026-06-19 | 99.80% | TrustPointe | View File | |
| KPV | KV202606 | WF03 | 2026-06-12 | 99.36% | TrustPointe | Yes | View File |
| BPC-157 | BC202607 | WF03 | 2026-06-12 | 99.82% | TrustPointe | Yes | View File |
| Ipamorelin | IP202606 | WF03 | 2026-06-12 | 99.98% | TrustPointe | Yes | View File |
| Semaglutide | SM202607 | VI32 | 2026-06-12 | 99.96% | TrustPointe | Yes | View File |
| Retatrutide | RTT202606 | WF03 | 2026-06-12 | 99.36% | Kovera | Yes | View File |
| CJC-1295 ND | CJ202606 | WF03 | 2026-06-10 | 99.88% | TrustPointe | Yes | View File |
| BPC-157 | BC202607 | WF03 | 2026-06-10 | 99.74% | Kovera | Yes | View File |
| Ipamorelin | IP202606 | WF03 | 2026-06-10 | 99.71% | Kovera | Yes | View File |
| Retatrutide | RT202607 | WF03 | 2026-06-09 | 99.76% | Kovera | View File | |
| Tirzepatide | TZ202605 | WF03 | 2026-06-09 | 99.55% | Kovera | Yes | View File |
| Semaglutide | SM202607 | VI32 | 2026-06-10 | 99.68% | Kovera | Yes | View File |
| KPV | KV202606 | WF03 | 2026-06-10 | 99.70% | Kovera | Yes | View File |
| Tirzepatide | TZ202605 | WF03 | 2026-06-10 | 99.34% | TrustPointe | Yes | View File |
| CJC-1295 ND | CJ202606 | WF03 | 2026-06-09 | 99.65% | Kovera | Yes | View File |
| Reconstitution Solution | BAC202603 | VI32 | 2026-06-09 | 99.90% | Kovera | Yes | View File |
| NAD+ | NDB202606 | WF03 | 2026-05-28 | 99.55% | TrustPointe | View File | |
| GHK-Cu | CU202605 | WF03 | 2026-05-13 | 99.67% | TrustPointe | View File | |
| Epithalon | ET202604 | WF03 | 2026-05-13 | 99.86% | Kovera | View File | |
| 5-Amino-1MQ | AM202604 | WF03 | 2026-05-13 | 99.78% | Kovera | Yes | View File |
| 5-Amino-1MQ | AM202604 | WF03 | 2026-05-29 | 99.53% | Chromate | Yes | View File |
| Reconstitution Solution | BAC202603 | VI32 | 2026-06-11 | 99.22% | TrustPointe | Yes | View File |
| MOTS-c | MC202605 | WF03 | 2026-06-08 | 99.98% | TrustPointe | View File | |
| Retatrutide | RTT202606 | WF03 | 2026-06-08 | 99.94% | TrustPointe | Yes | View File |
| TB-500 (TB4) | TB202605 | WF03 | 2026-05-28 | 99.76% | TrustPointe | View File | |
| Tesamorelin | TES202605 | WF03 | 2026-05-28 | 99.81% | TrustPointe | View File | |
| Retatrutide | RT202605 | WF03 | 2026-05-27 | 99.75% | TrustPointe | View File | |
| Reconstitution Solution | BAC202602 | VI32 | 2026-05-14 | 99.90% | Kovera | View File | |
| CJC-1295 ND / Ipamorelin | CJIP202605 | WF03 | 2026-05-14 | 99.93% | TrustPointe | View File | |
| Cagrilintide | CG202607 | WF03 | 2026-05-14 | 99.74% | TrustPointe | View File | |
| BPC-157/TB-500 | BB202605 | VI32 | 2026-05-14 | 99.73% | TrustPointe | Yes | View File |
| GHK-Cu | CU202604 | WF03 | 2026-05-14 | 99.74% | TrustPointe | Yes | View File |
| BPC-157 | BC202604 | VI32 | 2026-05-13 | 99.72% | TrustPointe | Yes | View File |
| CIT: CJC-1295 ND / Ipamorelin / Tesamorelin | CIT202604 | WF03 | 2026-05-07 | 99.82% | Kovera | View File | |
| Tesamorelin | TES202604 | WF03 | 2026-04-21 | 99.85% | Kovera | View File | |
| DSIP | DS202605 | WF03 | 2026-05-07 | 99.81% | Kovera | View File | |
| BPC-157/TB-500 | BB202605 | VI32 | 2026-04-21 | 99.90% | Kovera | Yes | View File |
| KLOW Blend | KW202604 | WF03 | 2026-04-21 | 99.86% | Kovera | View File | |
| AOD-9604 | AO202605 | WF03 | 2026-04-20 | 99.93% | Kovera | View File | |
| Cagrilintide | CG202603 | VI32 | 2026-04-14 | 99.90% | Kovera | View File | |
| MOTS-c | MC202603 | VI32 | 2026-04-04 | 99.96% | Kovera | View File | |
| Retatrutide | RT202604 | WF03 | 2026-04-16 | 99.54% | TrustPointe | View File | |
| Sermorelin | SER202601 | VI32 | 2026-04-01 | 99.94% | Kovera | View File | |
| Pinealon | PN202603 | WF03 | 2026-04-01 | 99.96% | Kovera | View File | |
| GHK-Cu | CU202604 | WF03 | 2026-04-03 | 99.93% | Kovera | Yes | View File |
| SS-31 | SS202601 | WF03 | 2026-04-03 | 99.82% | TrustPointe | View File | |
| Semax | SX202603 | WF03 | 2026-03-31 | 99.91% | Kovera | View File | |
| Retatrutide | RT202603 | WF03 | 2026-03-30 | 99.40% | TrustPointe | View File | |
| GLOW Blend | GW202603 | WF03 | 2026-03-25 | 99.88% | Kovera | View File | |
| Tirzepatide | TZ202603 | VI32 | 2026-03-27 | 99.89% | TrustPointe | View File | |
| BPC-157/TB-500 | BB202604 | WF03 | 2026-03-27 | 99.63% | TrustPointe | View File | |
| Tesamorelin | TES202603 | WF03 | 2026-03-25 | 99.52% | TrustPointe | View File | |
| BPC-157 | BC202604 | VI32 | 2026-03-18 | 99.60% | TrustPointe | Yes | View File |
| Ipamorelin/CJC-1295 (No DAC) | CJIP202602 | WF03 | 2026-02-27 | 99.92% | TrustPointe | View File | |
| Thymosin Alpha-1 | TA202602 | WF03 | 2026-02-25 | 99.95% | Kovera | View File | |
| KLOW | KW202602 | WF03 | 2026-03-01 | 99.86% | Chromate | View File | |
| NAD+ | NDB202601 | VI32 | 2026-02-07 | 99.92% | Kovera | View File | |
| SS-31 | SS202602 | WF03 | 2026-02-08 | 99.68% | Chromate | View File | |
| MOTS-c | MC202602 | WF03 | 2026-02-09 | 99.41% | Chromate | View File | |
| Selank | SEK202601 | VI32 | 2026-01-29 | 99.94% | Chromate | View File | |
| Unbuffered NAD+ | NDU202601 | MZ21 | 2026-01-20 | 99.85% | Chromate | View File | |
| KPV | KV202601 | VI32 | 2026-01-20 | 99.90% | Chromate | View File | |
| Ipamorelin | IP202601 | WF03 | 2026-01-14 | 99.92% | TrustPointe | View File | |
| TB500 (TB4) | TB202601 | WF03 | 2026-01-14 | 99.86% | TrustPointe | View File | |
| Retatrutide | RT202602 | WF03 | 2026-01-13 | 99.63% | TrustPointe | View File | |
| PT-141 | PT202512 | VI32 | 2026-01-12 | 99.89% | BioRegen | View File | |
| Semaglutide | SM202601 | MZ21 | 2026-01-10 | 99.70% | TrustPointe | View File | |
| Cagrilintide | CAG202601 | MZ21 | 2026-01-10 | 99.33% | TrustPointe | View File | |
| Tesamorelin | TES202601 | WF03 | 2025-12-29 | 99.71% | TrustPointe | View File | |
| BPC-157 | BP202512 | WF03 | 2025-12-29 | 99.46% | TrustPointe | View File | |
| BPC-157/TB-500 | BB202512 | WF03 | 2025-12-29 | 99.64% | TrustPointe | View File | |
| GHK-Cu | GK202512 | SH07 | 2025-12-19 | 99.79% | BioRegen | View File | |
| MOTS-c | MC202512 | WF03 | 2025-12-22 | 99.89% | BioRegen | View File | |
| Retatrutide | RP260130 | VI32 | 2025-12-22 | 99.72% | TrustPointe | View File | |
| SS-31 | SS202512 | WF03 | 2025-12-19 | 99.70% | TrustPointe | View File | |
| Retatrutide | RP202601 | DF05 | 2025-12-22 | 99.63% | TrustPointe | View File | |
| Ipamorelin/CJC-1295 (No DAC) | CJIP202512 | WF03 | 2025-12-09 | 99.80% | TrustPointe | View File | |
| Retatrutide | RP202511 | DF05 | 2025-12-19 | 99.73% | TrustPointe | View File | |
| Retatrutide | RP20251020 | DF05 | 2025-11-10 | 99.33% | TrustPointe | View File | |
| Retatrutide | RP20251001 | DF05 | 2025-10-13 | 99.86% | TrustPointe | View File | |
| Tirzepatide | TZ20250915 | DF05 | 2025-10-03 | 99.74% | TrustPointe | View File | |
| Retatrutide | RP20250929 | VI32 | 2025-10-03 | 99.47% | TrustPointe | View File | |
| Humanin | HP20250805 | WF03 | 2025-09-19 | 99.92% | BioRegen | View File | |
| MOTS-c | YC20250807 | WF03 | 2025-09-19 | 99.87% | BioRegen | View File | |
| DSIP | DS20250820 | SH07 | 2025-09-19 | 99.88% | BioRegen | View File | |
| SS-31 | SY20250806 | WF03 | 2025-09-19 | 99.70% | BioRegen | View File | |
| CJC/Ipamorelin | CI20250805 | WF03 | 2025-09-11 | 99.84% | TrustPointe | View File | |
| BPC-157 | BP20250808 | WF03 | 2025-09-05 | 99.99% | TrustPointe | View File | |
| Sermorelin | SM20250723 | WF03 | 2025-08-27 | 99.84% | BioRegen | View File | |
| Tesamorelin | TS20250722 | WF03 | 2025-08-22 | 99.10% | TrustPointe | View File | |
| CJC-1295 ND | CJ20250724 | WF03 | 2025-08-20 | 99.43% | TrustPointe | View File | |
| Semaglutide | SM20250801 | EJ12 | 2025-08-20 | 99.34% | TrustPointe | View File | |
| Ipamorelin | IP20250721 | WF03 | 2025-08-15 | 99.64% | TrustPointe | View File | |
| GHK-Cu | CU20250717 | SH07 | 2025-08-09 | 99.73% | BioRegen | View File | |
| Tirzepatide | TZ20250730 | EJ12 | 2025-08-08 | 99.41% | TrustPointe | View File | |
| NAD+ | ND20250503 | SH07 | 2025-07-31 | 99.76% | BioRegen | View File | |
| VIP | VP20250511 | SH07 | 2025-07-31 | 99.42% | BioRegen | View File | |
| Retatrutide | CD20250708 | SH07 | 2025-07-25 | 99.42% | TrustPointe | View File | |
| BPC/TB500 | BB20250630 | SH07 | 2025-07-17 | 99.52% | TrustPointe | View File | |
| TB500 (TB4) | TB20250614 | SH07 | 2025-07-17 | 99.68% | TrustPointe | View File |
Current Endotoxin Certifications
Swipe right to view full table →
| Peptide | Batch Id | Manufacturer | Date | USP Conformation | Laboratory | |
|---|---|---|---|---|---|---|
| Kisspeptin-10 | KSS2607 | VI32 | 2026-06-30 | Conforms | Kovera | View File |
| Reconstitution Solution | BAC202606 | WF03 | 2026-07-13 | Conforms | Kovera | View File |
| Retatrutide | RTT2613 | WF03 | 2026-06-30 | Conforms | Kovera | View File |
| Tesamorelin | TES202607 | WF03 | 2026-06-22 | Conforms | TrustPointe | View File |
| CJC-1295 ND | CJ202606 | WF03 | 2026-06-15 | Conforms | TrustPointe | View File |
| PT-141 | PT202605 | VI32 | 2026-06-12 | Conforms | Kovera | View File |
| Retatrutide | RTT202606 | WF03 | 2026-06-12 | Conforms | Kovera | View File |
| MOTS-c | MC202605 | WF03 | 2026-06-11 | Conforms | TrustPointe | View File |
| Semaglutide | SM202607 | VI32 | 2026-06-10 | Conforms | Kovera | View File |
| Ipamorelin | IP202606 | WF03 | 2026-06-10 | Conforms | Kovera | View File |
| KPV | KV202606 | WF03 | 2026-06-10 | Conforms | Kovera | View File |
| BPC-157 | BC202607 | WF03 | 2026-06-10 | Conforms | Kovera | View File |
| Retatrutide | RT202607 | WF03 | 2026-06-09 | Conforms | Kovera | View File |
| Tirzepatide | TZ202605 | WF03 | 2026-06-09 | Conforms | Kovera | View File |
| Reconstitution Solution | BAC202603 | VI32 | 2026-06-09 | Conforms | Kovera | View File |
| Reconstitution Solution | BAC202603 | VI32 | 2026-06-11 | Conforms | TrustPointe | View File |
| Epithalon | ET202604 | WF03 | 2026-05-13 | Conforms | Kovera | View File |
| 5-Amino-1MQ | AM202604 | WF03 | 2026-05-13 | Conforms | Kovera | View File |
| NAD+ | NDB202606 | WF03 | 2026-05-28 | Conforms | TrustPointe | View File |
| TB-500 (TB4) | TB202605 | WF03 | 2026-05-28 | Conforms | TrustPointe | View File |
| Tesamorelin | TES202605 | WF03 | 2026-05-28 | Conforms | TrustPointe | View File |
| Retatrutide | RT202605 | WF03 | 2026-05-27 | Conforms | TrustPointe | View File |
| CJC-1295 ND / Ipamorelin | CJIP202605 | WF03 | 2026-05-14 | Conforms | TrustPointe | View File |
| GHK-Cu | CU202605 | WF03 | 2026-05-18 | Conforms | TrustPointe | View File |
| Cagrilintide | CG202607 | WF03 | 2026-05-18 | Conforms | TrustPointe | View File |
| CIT: CJC-1295 ND / Ipamorelin / Tesamorelin | CIT202604 | WF03 | 2026-05-07 | Conforms | Kovera | View File |
| Tesamorelin | TES202604 | WF03 | 2026-04-21 | Conforms | Kovera | View File |
| DSIP | DS202605 | WF03 | 2026-05-07 | Conforms | Kovera | View File |
| BPC-157/TB-500 | BB202605 | VI32 | 2026-04-21 | Conforms | Kovera | View File |
| KLOW Blend | KW202604 | WF03 | 2026-04-21 | Conforms | Kovera | View File |
| AOD-9604 | AO202605 | WF03 | 2026-04-20 | Conforms | Kovera | View File |
| Retatrutide | RT202604 | WF03 | 2026-04-16 | Conforms | TrustPointe | View File |
| MOTS-c | MC202603 | VI32 | 2026-04-04 | Conforms | Kovera | View File |
| Pinealon | PN202603 | WF03 | 2026-04-01 | Conforms | Kovera | View File |
| Cagrilintide | CG202603 | VI32 | 2026-04-14 | Conforms | Kovera | View File |
| Sermorelin | SER202601 | VI32 | 2026-04-01 | Conforms | Kovera | View File |
| GHK-Cu | CU202604 | WF03 | 2026-04-03 | Conforms | Kovera | View File |
| SS-31 | SS202601 | WF03 | 2026-04-03 | Conforms | TrustPointe | View File |
| Semax | SX202603 | WF03 | 2026-03-31 | Conforms | Kovera | View File |
| Retatrutide | RT202603 | WF03 | 2026-03-30 | Conforms | TrustPointe | View File |
| GLOW Blend | GW202603 | WF03 | 2026-03-25 | Conforms | Kovera | View File |
| Tirzepatide | TZ202603 | VI32 | 2026-03-27 | Conforms | TrustPointe | View File |
| BPC-157/TB-500 | BB202604 | WF03 | 2026-03-26 | Conforms | TrustPointe | View File |
| Tesamorelin | TES202603 | WF03 | 2026-03-25 | Conforms | TrustPointe | View File |
| SS-31 | SS202602 | WF03 | 2026-02-25 | Conforms | Kovera | View File |
| CJC-1295 ND/Ipamorelin | CJIP202602 | WF03 | 2026-02-25 | Conforms | Kovera | View File |
| KLOW Blend | KW202602 | WF03 | 2026-02-25 | Conforms | Kovera | View File |
| BPC-157 | BC202604 | WF03 | 2026-03-17 | Conforms | Kovera | View File |
| Thymosin Alpha-1 | TA202601 | WF03 | 2026-02-25 | Conforms | Kovera | View File |
| MOTS-c | MC202602 | WF03 | 2026-02-08 | Conforms | Kovera | View File |
| NAD+ | NDB202601 | VI32 | 2026-02-08 | Conforms | Kovera | View File |
| Unbuffered NAD+ | NDU202601 | MZ21 | 2026-01-28 | Conforms | TrustPointe | View File |
| KPV | KV202601 | VI32 | 2026-01-28 | Conforms | TrustPointe | View File |
| Ipamorelin | IP202601 | WF03 | 2026-01-13 | Conforms | TrustPointe | View File |
| TB500 | TB202601 | WF03 | 2026-01-13 | Conforms | TrustPointe | View File |
| Retatrutide | RT202602 | WF03 | 2026-01-13 | Conforms | TrustPointe | View File |
| PT-141 | PT202512 | VI32 | 2026-01-07 | Conforms | BioRegen | View File |
| Semaglutide | SM202601 | MZ21 | 2026-01-10 | Conforms | TrustPointe | View File |
| Cagrilintide | CAG202601 | MZ21 | 2026-01-10 | Conforms | TrustPointe | View File |
| Tesamorelin | TES202601 | WF03 | 2026-01-06 | Conforms | TrustPointe | View File |
| BPC-157 | BP202512 | WF03 | 2025-12-30 | Conforms | TrustPointe | View File |
| BPC-157/TB-500 | BB202512 | WF03 | 2025-12-30 | Conforms | TrustPointe | View File |
| Retatrutide | RP260130 | DF05 | 2025-12-22 | Conforms | TrustPointe | View File |
| SS-31 | SS202512 | WF03 | 2025-12-19 | Conforms | TrustPointe | View File |
| Retatrutide | RP202601 | DF05 | 2025-12-22 | Conforms | TrustPointe | View File |
| Ipamorelin/CJC-1295 (No DAC) | CJIP202512 | WF03 | 2025-12-08 | Conforms | TrustPointe | View File |
| Retatrutide | RP202511 | DF05 | 2025-11-10 | Conforms | TrustPointe | View File |
| Retatrutide | RP20251020 | DF05 | 2025-11-10 | Conforms | TrustPointe | View File |
| Retatrutide | RP20251001 | DF05 | 2025-10-13 | Conforms | TrustPointe | View File |
| Tirzepatide | TZ20250915 | DF05 | 2025-10-03 | Conforms | TrustPointe | View File |
| Retatrutide | RP20250929 | VI32 | 2025-10-03 | Conforms | TrustPointe | View File |
| Humanin | HP20250805 | WF03 | 2025-09-19 | Conforms | BioRegen | View File |
| MOTS-c | YC20250807 | WF03 | 2025-09-19 | Conforms | BioRegen | View File |
| DSIP | DS20250820 | SH07 | 2025-09-19 | Conforms | BioRegen | View File |
| SS-31 | SY20250806 | WF03 | 2025-09-19 | Conforms | BioRegen | View File |
| CJC/Ipamorelin | CI20250805 | WF03 | 2025-09-03 | Conforms | TrustPointe | View File |
| BPC-157 | BP20250808 | WF03 | 2025-09-03 | Conforms | TrustPointe | View File |
| Bacteriostatic Water | BAC20250807 | SH07 | 2025-08-27 | Conforms | BioRegen | View File |
| Tesamorelin | TS20250722 | WF03 | 2025-08-20 | Conforms | TrustPointe | View File |
| CJC-1295 ND | CJ20250724 | WF03 | 2025-08-20 | Conforms | TrustPointe | View File |
| Sermorelin | SM20250723 | WF03 | 2025-08-20 | Conforms | TrustPointe | View File |
| Semaglutide | SM20250801 | EJ12 | 2025-08-20 | Conforms | TrustPointe | View File |
| Ipamorelin | IP20250721 | WF03 | 2025-08-11 | Conforms | TrustPointe | View File |
| GHK-Cu | CU20250717 | SH07 | 2025-08-08 | Conforms | TrustPointe | View File |
| Tirzepatide | TZ20250730 | EJ12 | 2025-08-04 | Conforms | TrustPointe | View File |
| NAD+ | ND20250503 | SH07 | 2025-07-29 | Conforms | TrustPointe | View File |
| VIP | VP20250511 | SH07 | 2025-07-29 | Conforms | TrustPointe | View File |
| Retatrutide | CD20250708 | SH07 | 2025-07-24 | Conforms | TrustPointe | View File |
| BPC/TB500 | BB20250630 | SH07 | 2025-07-17 | Conforms | TrustPointe | View File |
| TB500 (TB4) | TB20250614 | SH07 | 2025-07-17 | Conforms | TrustPointe | View File |
Current Heavy Metal Certifications
Swipe right to view full table →
| Peptide | Batch Id | Manufacturer | Date | Class 1 USP | Full USP | Laboratory |
|---|---|---|---|---|---|---|
| Kisspeptin-10 | KSS2607 | VI32 | 2026-07-01 | Conforms | Kovera | View File |
| Retatrutide | RTT2613 | WF03 | 2026-07-01 | Conforms | Kovera | View File |
| Ipamorelin | IP202606 | WF03 | 2026-06-26 | Conforms | TrustPointe | View File |
| KPV | KV202606 | WF03 | 2026-06-26 | Conforms | TrustPointe | View File |
| BPC-157 | BC202607 | WF03 | 2026-06-26 | Conforms | TrustPointe | View File |
| Tesamorelin | TES202607 | WF03 | 2026-06-26 | Conforms | TrustPointe | View File |
| Semaglutide | SM202607 | VI32 | 2026-06-25 | Conforms | TrustPointe | View File |
| CJC-1295 ND | CJ202606 | WF03 | 2026-06-25 | Conforms | TrustPointe | View File |
| Retatrutide | RT202607 | WF03 | 2026-06-25 | Conforms | TrustPointe | View File |
| Tirzepatide | TZ202605 | WF03 | 2026-06-25 | Conforms | TrustPointe | View File |
| Retatrutide | RTT202606 | WF03 | 2026-06-25 | Conforms | TrustPointe | View File |
| MOTS-c | MC202605 | WF03 | 2026-06-25 | Conforms | TrustPointe | View File |
| PT-141 | PT202605 | VI32 | 2026-06-13 | Conforms | Kovera | View File |
| Retatrutide | RTT202606 | WF03 | 2026-06-12 | Conforms | Kovera | View File |
| Semaglutide | SM202607 | VI32 | 2026-06-11 | Conforms | Kovera | View File |
| Ipamorelin | IP202606 | WF03 | 2026-06-11 | Conforms | Kovera | View File |
| KPV | KV202606 | WF03 | 2026-06-11 | Conforms | Kovera | View File |
| BPC-157 | BC202607 | WF03 | 2026-06-11 | Conforms | Kovera | View File |
| Retatrutide | RT202607 | WF03 | 2026-06-11 | Conforms | Kovera | View File |
| Tirzepatide | TZ202605 | WF03 | 2026-06-10 | Conforms | Kovera | View File |
| Epithalon | ET202604 | WF03 | 2026-05-14 | Conforms | Kovera | View File |
| 5-Amino-1MQ | AM202604 | WF03 | 2026-05-14 | Conforms | Kovera | View File |
| NAD+ | NDB202606 | WF03 | 2026-06-05 | Conforms | TrustPointe | View File |
| Tesamorelin | TES202605 | WF03 | 2026-06-05 | Conforms | TrustPointe | View File |
| Retatrutide | RT202605 | WF03 | 2026-06-05 | Conforms | TrustPointe | View File |
| TB-500 | TB202605 | WF03 | 2026-06-05 | Conforms | TrustPointe | View File |
| GHK-Cu | CU202605 | WF03 | 2026-05-26 | Conforms | TrustPointe | View File |
| CJC-1295 ND / Ipamorelin | CJIP202605 | WF03 | 2026-05-26 | Conforms | TrustPointe | View File |
| Cagrilintide | CG202607 | WF03 | 2026-05-26 | Conforms | TrustPointe | View File |
| SS-31 | SS202602 | WF03 | 2026-05-24 | Conforms | TrustPointe | View File |
| AOD-9604 | AO202605 | WF03 | 2026-05-24 | Conforms | TrustPointe | View File |
| GLOW Blend | GW202603 | WF03 | 2026-05-24 | Conforms | TrustPointe | View File |
| KLOW Blend | KW202602 | WF03 | 2026-05-24 | Conforms | TrustPointe | View File |
| CJC-1295 ND / Ipamorelin | CJIP202605 | WF03 | 2026-05-16 | Conforms | Kovera | View File |
| Cagrilintide | CG202607 | WF03 | 2026-05-16 | Conforms | Kovera | View File |
| CIT: CJC-1295 ND / Ipamorelin / Tesamorelin | CIT202604 | WF03 | 2026-04-26 | Conforms | Kovera | View File |
| Tesamorelin | TES202604 | WF03 | 2026-04-22 | Conforms | Kovera | View File |
| Pinealon | PN202603 | WF03 | 2026-05-05 | Conforms | TrustPointe | View File |
| Semax | SX202603 | WF03 | 2026-05-05 | Conforms | TrustPointe | View File |
| MOTS-c | MC202602 | WF03 | 2026-05-05 | Conforms | TrustPointe | View File |
| Cagrilintide | CG202603 | VI32 | 2026-05-05 | Conforms | TrustPointe | View File |
| SS-31 | SS202601 | WF03 | 2026-05-05 | Conforms | TrustPointe | View File |
| CJC-1295 ND/Ipamorelin | CJIP202602 | WF03 | 2026-05-05 | Conforms | TrustPointe | View File |
| DSIP | DS202605 | WF03 | 2026-04-24 | Conforms | Kovera | View File |
| BPC-157/TB-500 | BB202605 | VI32 | 2026-04-21 | Conforms | Kovera | View File |
| KLOW Blend | KW202604 | WF03 | 2026-04-21 | Conforms | Kovera | View File |
| Retatrutide | RT202604 | WF03 | 2026-04-22 | Conforms | Kovera | View File |
| AOD-9604 | AO202605 | WF03 | 2026-04-20 | Conforms | Kovera | View File |
| SS-31 | SS202601 | WF03 | 2026-04-02 | Conforms | Kovera | View File |
| BPC-157/TB-500 | BB202604 | WF03 | 2026-04-03 | Conforms | TrustPointe | View File |
| Cagrilintide | CG202603 | VI32 | 2026-03-31 | Conforms | Kovera | View File |
| Pinealon | PN202603 | WF03 | 2026-04-01 | Conforms | Kovera | View File |
| GLOW Blend | GW202603 | WF03 | 2026-04-01 | Conforms | Kovera | View File |
| KLOW Blend | KW202602 | WF03 | 2026-04-01 | Conforms | Kovera | View File |
| CJC-1295 ND/Ipamorelin | CJIP202602 | WF03 | 2026-04-01 | Conforms | Kovera | View File |
| SS-31 | SS202602 | WF03 | 2026-04-01 | Conforms | Kovera | View File |
| MOTS-c | MC202602 | WF03 | 2026-04-01 | Conforms | Kovera | View File |
| Tesamorelin | TES202603 | WF03 | 2026-04-03 | Conforms | TrustPointe | View File |
| Sermorelin | SER202601 | VI32 | 2026-03-29 | Conforms | Kovera | View File |
| MOTS-c | MC202603 | VI32 | 2026-04-01 | Conforms | Kovera | View File |
| Retatrutide | RT202603 | WF03 | 2026-04-03 | Conforms | TrustPointe | View File |
| Semax | SX202603 | WF03 | 2026-03-31 | Conforms | Kovera | View File |
| GLOW Blend | GW202603 | WF03 | 2026-03-26 | Conforms | Kovera | View File |
| Tirzepatide | TZ202603 | VI32 | 2026-03-26 | Conforms | Kovera | View File |
| BPC-157 | BC202604 | WF03 | 2026-03-17 | Conforms | Kovera | View File |
| Thymosin Alpha-1 | TA202602 | WF03 | 2026-02-25 | Conforms | Kovera | View File |
| NAD+ | NDB202601 | VI32 | 2026-02-08 | Conforms | Kovera | View File |
| Ipamorelin | IP202601 | WF03 | 2026-01-26 | Conforms | TrustPointe | View File |
| TB500 | TB202601 | WF03 | 2026-01-26 | Conforms | TrustPointe | View File |
| Retatrutide | RT202602 | WF03 | 2026-01-26 | Conforms | TrustPointe | View File |
| Semaglutide | SM202601 | MZ21 | 2026-01-19 | Conforms | TrustPointe | View File |
| Cagrilintide | CAG202601 | MZ21 | 2026-01-19 | Conforms | TrustPointe | View File |
| Tesamorelin | TES202601 | WF03 | 2026-01-19 | Conforms | TrustPointe | View File |
| BPC-157 | BP202512 | WF03 | 2026-01-08 | Conforms | TrustPointe | View File |
| BPC-157/TB-500 | BB202512 | WF03 | 2026-01-08 | Conforms | TrustPointe | View File |
| Tirzepatide | TZ20250915 | DF05 | 2025-12-03 | Conforms | TrustPointe | View File |
| TB500 (TB4) | TB20250614 | SH07 | 2025-11-24 | Conforms | TrustPointe | View File |
| BPC-157 | BP20250808 | WF03 | 2025-11-12 | Conforms | TrustPointe | View File |
| BPC/TB500 | BB20250630 | SH07 | 2025-11-12 | Conforms | TrustPointe | View File |
| CJC-1295 ND | CJ20250724 | WF03 | 2025-11-12 | Conforms | TrustPointe | View File |
| GHK-Cu | CU20250717 | SH07 | 2025-11-12 | Conforms | TrustPointe | View File |
| Ipamorelin | IP20250721 | WF03 | 2025-11-12 | Conforms | TrustPointe | View File |
| Retatrutide | RP20251020 | DF05 | 2025-11-12 | Conforms | TrustPointe | View File |
| Sermorelin | SM20250723 | WF03 | 2025-11-12 | Conforms | TrustPointe | View File |
| SS-31 | SY20250806 | WF03 | 2025-11-12 | Conforms | TrustPointe | View File |
| TB500 (TB4) | TB20250614 | SH07 | 2025-11-12 | Conforms | TrustPointe | View File |
| Tesamorelin | TS20250722 | WF03 | 2025-11-12 | Conforms | TrustPointe | View File |
| Tirzepatide | TZ20250730 | EJ12 | 2025-11-12 | Conforms | TrustPointe | View File |
Current Sterility Certifications
Swipe right to view full table →
| Product | Batch Id | Manufacturer | Date | USP Pass/Fail | Rapid Pass/Fail | Laboratory | File |
|---|---|---|---|---|---|---|---|
| Kisspeptin-10 | KSS2607 | VI32 | 2026-06-30 | Pass | Kovera | View File | |
| Retatrutide | RTT2613 | WF03 | 2026-06-30 | Pass | Kovera | View File | |
| CJC-1295 ND | CJ202606 | WF03 | 2026-06-26 | Pass | TrustPointe | View File | |
| Ipamorelin | IP202606 | WF03 | 2026-06-26 | Pass | TrustPointe | View File | |
| Reconstitution Solution | BAC202603 | VI32 | 2026-06-26 | Pass | TrustPointe | View File | |
| MOTS-c | MC202605 | WF03 | 2026-06-23 | Pass | TrustPointe | View File | |
| NAD+ | NDB202606 | WF03 | 2026-06-15 | Pass | TrustPointe | View File | |
| Tesamorelin | TES202605 | WF03 | 2026-06-15 | Pass | TrustPointe | View File | |
| Retatrutide | RTT202606 | WF03 | 2026-06-12 | Pass | Kovera | View File | |
| PT-141 | PT202605 | VI32 | 2026-06-12 | Pass | Kovera | View File | |
| Semaglutide | SM202607 | VI32 | 2026-06-10 | Pass | Kovera | View File | |
| Ipamorelin | IP202606 | WF03 | 2026-06-10 | Pass | Kovera | View File | |
| KPV | KV202606 | WF03 | 2026-06-10 | Pass | Kovera | View File | |
| BPC-157 | BC202607 | WF03 | 2026-06-10 | Pass | Kovera | View File | |
| Retatrutide | RT202605 | WF03 | 2026-06-12 | Pass | Kovera | View File | |
| CJC-1295 ND | CJ202606 | WF03 | 2026-06-09 | Pass | Kovera | View File | |
| Retatrutide | RT202607 | WF03 | 2026-06-09 | Pass | Kovera | View File | |
| Tirzepatide | TZ202605 | WF03 | 2026-06-09 | Pass | Kovera | View File | |
| Epithalon | ET202604 | WF03 | 2026-05-14 | Pass | Kovera | View File | |
| GHK-Cu | CU202605 | WF03 | 2026-05-29 | Pass | TrustPointe | View File | |
| Epithalon | ET202604 | WF03 | 2026-05-14 | Pass | Kovera | View File | |
| 5-Amino-1MQ | AM202604 | WF03 | 2026-05-14 | Pass | Kovera | View File | |
| Reconstitution Solution | BAC202602 | VI32 | 2026-05-14 | Pass | Kovera | View File | |
| CJC-1295 ND / Ipamorelin | CJIP202605 | WF03 | 2026-05-14 | Pass | Kovera | View File | |
| Cagrilintide | CG202607 | VI32 | 2026-05-14 | Pass | Kovera | View File | |
| CIT: CJC-1295 ND / Ipamorelin / Tesamorelin | CIT202604 | WF03 | 2026-05-07 | Pass | Kovera | View File | |
| DSIP | DS202605 | WF03 | 2026-05-07 | Pass | – | Kovera | View File |
| BPC-157/TB-500 | BB202605 | VI32 | 2026-04-21 | Pass | Kovera | View File | |
| Retatrutide | RT202604 | WF03 | 2026-04-22 | Pass | – | Kovera | View File |
| KLOW Blend | KW202604 | WF03 | 2026-04-21 | – | Pass | Kovera | View File |
| AOD-9604 | AO202605 | WF03 | 2026-04-20 | – | Pass | Kovera | View File |
| Cagrilintide | CG202603 | VI32 | 2026-04-12 | Pass | – | Kovera | View File |
| SS-31 | SS202601 | WF03 | 2026-04-12 | – | Pass | Kovera | View File |
| MOTS-c | MC202603 | VI32 | 2026-04-04 | Pass | – | Kovera | View File |
| Bacteriostatic Water | BAC202601 | WF03 | 2026-01-13 | Pass | – | TrustPointe | View File |
| Bacteriostatic Water | BAC20250807 | SH07 | 2025-09-09 | Pass | – | TrustPointe | View File |
| Meta-Z | MZR20250713 | DF05 | 2025-08-26 | Pass | – | TrustPointe | View File |
Verifiable certificates
When obtaining research peptides, it is essential to validate the authenticity of the Certificate of Analysis (COA). Certificate fraud runs rampant throughout the research peptide supply community. The two most common forms are doctored images and stolen certificates. You can check for these two by making sure the third-party laboratory’s website shows that the certificate belongs to the supplier and the values haven’t been doctored. TrustPointe Analytics provides a few simple rules for verification:
When obtaining research peptides, it is essential to validate the authenticity of the Certificate of Analysis (COA). Certificate fraud runs rampant throughout the research peptide supply community. The two most common forms are doctored images and stolen certificates. You can check for these two by making sure the third-party laboratory’s website shows that the certificate belongs to the supplier and the values haven’t been doctored. TrustPointe Analytics provides a few simple rules for verification:
Beware of fraudulent laboratories
Not only must one remain vigilant about potentially fraudulent certificates, one must also be aware that there are third-party laboratories whose results cannot be considered reliable or scientifically valid. Unfortunately, there is significant evidence to suggest that one of the most popular third-party testing labs does not use scientifically sound methodologies and, in some cases, has fabricated results. There isn’t an easy remedy for this problem, but when labs are particularly bad, there tend to be a lot of discussion threads on various social platforms.
Interpreting Endotoxin Results (via TrustPointe)
Our friends at TrustPointe have provided the following detailed explanation to help interpret the results of the endotoxin testing.
We use the Charles River Endosafe PTS system to test for bacterial endotoxins following USP <85> guidelines:
- USP <85> Bacterial Endotoxin Result: <x.xx EU/mL
Because it’s reported as “<x.xx” this indicates the test did not detect endotoxin above the detection limit of the cartridge. - If a result is above the limit of detection of the cartridge, it will be reported as a number (without the “<“).
The following are suitability parameters that verify the system was working properly and the sample prep dilution is appropriate for accurate results. Peptides often interfere with endotoxin detection due to their tendency to bind or mask endotoxins, which can lead to inaccurate low results. To overcome this, samples are typically tested at a large dilution to reduce matrix interference and ensure reliable recovery and detection in compliance with USP <85>. If the dilution is not correct, the run will fail suitability and we’ll need to adjust the dilution to ensure accurate results. We provide the suitability data to customers for transparency and so they can be confident in the results.
USP <85> Sample CV %:
- CV stands for coefficient of variation, a measure of repeatability.
- For our lab, CV has to be <25% or the result to be considered valid
USP <85> Spike CV %:
- This refers to the precision of the positive control (spiked sample).
- Again, for our lab CV has to be <25% or the result to be considered valid
USP <85> Spike Recovery
- This tells us how much of the known endotoxin spike was recovered from your sample.
- The acceptable range is 50–200% per USP <85>
NOT SUITABLE FOR HUMAN CONSUMPTION – INTENDED FOR RESEARCH ONLY
Thank you for choosing Peptide Partners.
NOTICE: All information provided above is strictly intended for educational and informational purposes. Our products are designed for research use solely and are not approved for human consumption. Please refrain from any form of ingestion.
By making a purchase from Peptide Partners, you acknowledge that you are acquiring Research Chemicals. Our products are exclusively intended for laboratory research purposes.
It is imperative that only qualified and licensed professionals handle this product. Under no circumstances should it be utilized as a drug, agricultural or pesticide product, food additive, or household chemical. Misrepresentation of this product for such purposes is strictly prohibited by law. All content on our website is provided for educational use exclusively. Any form of introduction into the human or animal body is illegal.
Related products
Metabolics
Metabolics
Metabolics
Metabolics
Metabolics
Metabolics
Metabolics